– NASDAQ:APM
Founder-led company
stock price today
$1.29
+0.21
+19.45%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 2 hours
stock price monthly change
-76.16%
month
stock price quarterly change
-76.16%
quarter
stock price yearly change
-57.65%
year
key metrics
Market Cap | 3.68M |
Enterprise value | 6.51M |
P/E | -0.89 |
EV/Sales | 5.22 |
EV/EBITDA | N/A |
Price/Sales | 5.66 |
Price/Book | 0.31 |
PEG ratio | N/A |
EPS | -3.67 |
Revenue | N/A |
EBITDA | -25.70M |
Income | -12.62M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -3188.35% |
Oper. margin | -2890.36% |
Gross margin | -24.31% |
EBIT margin | -2890.36% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freestock price history
stock forecast
financial statements
| Jun 2022 | 527.46K | -1.88M | -357.42% |
|---|---|---|---|
| Dec 2022 | 768.42K | -7.91M | -1029.94% |
| Jun 2023 | 431.37K | -5.48M | -1271.99% |
| Dec 2023 | 0 | 2.66M |
| 2025 | 65.7M | 4.97M | 7.57% |
|---|---|---|---|
| 2026 | 106.8M | 14.01M | 13.12% |
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | |
|---|---|
| 2020 | 0.98% |
| 2021 | |
| 2022 | |
| 2023 |
| Dec 2022 | 20867371 | 13.03M | 62.46% |
|---|---|---|---|
| Feb 2023 | 0 | 0 | |
| Jun 2023 | 14412041 | 1.63M | 11.33% |
| Dec 2023 | 20640091 | 5.25M | 25.47% |
| Jun 2022 | -6.80M | 2.71M | 3.02M |
|---|---|---|---|
| Dec 2022 | -5.46M | -266.56K | 3.54M |
| Jun 2023 | -6.24M | 558.78K | 1.14M |
| Dec 2023 | -1.53M | 65.98K | 3.00M |
alternative data
| Aug 2023 | 18 |
|---|---|
| Sep 2023 | 18 |
| Oct 2023 | 18 |
| Nov 2023 | 18 |
| Dec 2023 | 18 |
| Jan 2024 | 18 |
| Feb 2024 | 18 |
| Mar 2024 | 18 |
| Apr 2024 | 18 |
| May 2024 | 18 |
| Jun 2024 | 3 |
| Jul 2024 | 3 |
other data
0.55%
-0.96%
of APM is owned by hedge funds
1.95K
-51.78K
shares is hold by hedge funds
| Insider | Compensation |
|---|---|
Mr. Chung Yuen Huen (1980) Founder, Chairman & Chief Executive Officer | $474,530 |
Dr. Clark Cheng (1980) Chief Medical Officer & Executive Director | $465,260 |
Dr. Wai Yip Lee (1974) Head of R&D | $405,200 |
Ms. Sabrina Khan (1982) Chief Financial Officer & Company Sec. | $372,540 |
Mr. Darren Lui (1981) Pres & Executive Director | $256,540 |
-
What's the price of stock today?
One share of stock can currently be purchased for approximately $1.29.
-
When is 's next earnings date?
Unfortunately, 's (APM) next earnings date is currently unknown.
-
Does pay dividends?
No, does not pay dividends.
-
How much money does make?
has a market capitalization of 3.68M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 66.71% to 431.38K US dollars.
-
What is 's stock symbol?
null is traded on the NASDAQ under the ticker symbol "APM".
-
What is 's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ?
Shares of can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are 's key executives?
's management team includes the following people:
- Mr. Chung Yuen Huen Founder, Chairman & Chief Executive Officer(age: 45, pay: $474,530)
- Dr. Clark Cheng Chief Medical Officer & Executive Director(age: 45, pay: $465,260)
- Dr. Wai Yip Lee Head of R&D(age: 51, pay: $405,200)
- Ms. Sabrina Khan Chief Financial Officer & Company Sec.(age: 43, pay: $372,540)
- Mr. Darren Lui Pres & Executive Director(age: 44, pay: $256,540)
-
Is founder-led company?
Yes, is a company led by its founder Mr. Chung Yuen Huen.
-
How many employees does have?
As Jul 2024, employs 3 workers, which is 83% less then previous quarter.
-
When went public?
null is publicly traded company for more then 6 years since IPO on 18 Dec 2018.
-
What is 's official website?
The official website for is aptorumgroup.com.
-
How can i contact ?
can be reached via phone at +44 20 8092 9299.
company profile:
Exchange:
NASDAQ
Full time employees:
3
Industry:
Biotechnology
Sector:
Healthcare
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
17 Hanover Square
London, W1S 1BN
London, W1S 1BN
CIK: 0001734005
ISIN: KYG6096M1226
CUSIP: G6096M106
